Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SCY-078 (Ibrexafungerp) DDI with Pravastatin in Healthy Subjects
NCT04092751Phase 1Completed
- Sponsor
- SCYNEXIS, Inc.
- Start
- Nov 2019
- Primary completion
- Dec 2019
- Modality
- Allosteric Modulators
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of ibrexafungerp in candidiasis (2 arms), sponsored by SCYNEXIS, Inc. Primary endpoint: Area Under the Curve at 24 days. Started Nov 2019; status: completed.
02
Drugs
ibrexafungerp
03
Conditions
candidiasis
Beyond the preview
Go deeper on NCT04092751.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04092751.